Gastrointestinal Malignancies Clinical Trials

Showing 31-35 of 35 items
31.
32.
33.
34.
35.
  • BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer
  • This is an open-label, three-part Phase 1/2 study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of trametinib (GSK1120212) and dabrafenib (GSK2118436) when administered in combination with the anti-EGFR antibody panitumumab in subjects with BRAF-mutation V600E or V600K positive colorectal cancer (CRC). Part 1 of the study will consist of dose-escalation cohorts Part 2 of the study will consist of expansion cohorts to investigate safety and clinical activity, and Part 3 of the study will be a randomized Phase II study comparing both the dabrafenib/panitumumab and dabrafenib/trametinib/panitumumab combinations to a chemotherapy comparator with respect to safety and clinical activity.
  • Diagnoses: Gastrointestinal Malignancies
  • Status: Recruiting
Showing 31-35 of 35 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms